7005 Taschereau Boulevard, suite 340, Brossard, QC J4Z 1A7, Canada
+1 (450)-678-8882
History & Certification
Tracing back to a founding desire to develop products and services in the health care technology market, CARA was developed in its entirety by imaging scientists at DIAGNOS. Early inspirations came from the body of publically available research published on the subject of retinal image analysis. These inspirations coupled with DIAGNOS’ existing base of expertise led to rapid progress being made.

CARA project was launched in 2005 as part of ongoing DIAGNOS Research and Development program under a corporate business diversification strategy.

CARA beta was released in the spring of 2009, and a formal management team was assembled shortly thereafter.

Diagnos received IOS 13 485 certification in the summer of 2009 and Health Canada registration.

2010 was a year of many local and international field trials aimed at testing the CARA product, service and target market.

US Food and Drug administration registration in the summer 2011.

CE Mark European Union registration in the spring of 2012.

Commonalities with Natural Resources
In application our technology look to identify anomalies in large quantities of complex data: help patients preserve vision health. These sorts of analyses are what our team of experts are most adept at building and automating. At a more granular level however, CARA has a proprietary “task scheduling engine” called Prognos (TM). Prognos is our means to balance the execution load of many complex and resource intensive transactions on our powerful multi-processor servers.
We are often asked if CARA is compliant with various national and international clinical care guidelines. In fact CARA as a platform is an enabler of screening in clinical practice, and DIAGNOS does not dictate or prescribe a particular set of guidelines over others.
() () () () () () () () () () () () () ()